Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars

Overview

Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 – 73.2/100,000, predominantly in women in mid adulthood. Cutaneous lesions occur in about 75-80% of patients with systemic lupus erythematodes.These lesions unfortunately and invariably lead to significant scarring and postinflammatory hypo- and hyperpigmentation. Several studies have reported that laser treatments in patients with CLE have a positive effect and safety. However, only few case reports exist about the effect of ablative lasers such as Carbon Dioxide (CO2) and Erbium-doped Yttrium Aluminum Garnet (Er:YAG) lasers in CLE scarring. Although no study shows a flare-up of CLE after laser treatment of the scars, many physicians are afraid of treating these often stigmatizing scars. Considering the huge psychological impact of facial scaring on quality of life, it is essential to explore and assess the value of already well-established treatment options for the management of scars also in patients with cutaneous lupus erythematodes. Hereby the study seeks the subjective and objective improvement of the CLE-scars after treatment with fractional Er:YAG laser compared to control (untreated) areas.

Full Title of Study: “Within-subject, Investigator Initiated, Single-blind, Single-centre, Randomized Clinical Trial Investigating the Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: August 1, 2022

Interventions

  • Device: Er:YAG laser
    • Treatment of scars with fractional Er:YAG 2940nm laser.

Arms, Groups and Cohorts

  • Experimental: Er:YAG laser
    • Treatment of scars with fractional Er:YAG 2940nm laser.
  • No Intervention: Control area
    • No treatment performed on control areas.

Clinical Trial Outcome Measures

Primary Measures

  • Average reduction of POSAS scar severity measure.
    • Time Frame: 24 weeks
    • Average reduction from baseline of Patient and Observer Scar Assessment Scale (POSAS), ranging from 12 to 120 with higher score indicating a worst condition.

Secondary Measures

  • Cumulative incidence of localized disease flare-up.
    • Time Frame: 4, 8, 12, 16 and 24 weeks
    • Cumulative incidence of disease flare-up defined according to localized Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) difference from baseline of 1 point or above. The localized RCLASI ranges from 0 to 13, with higher scores indicating a worst local disease activity.
  • Overall average reduction of POSAS scar severity measure.
    • Time Frame: 16 and 24 weeks
    • Overall average reduction from baseline of Patient and Observer Scar Assessment Scale (POSAS), ranging from 12 to 120 with higher score indicating a worst condition.
  • Overall average scar improvement according to physician global assessment.
    • Time Frame: 4, 8, 12, 16 and 24 weeks
    • Overall average scar improvement from baseline according to a 6-point Physician Global Assessment (PGA) scale, based on before-after pictures of lesions assessment, ranging from 1 to 6, with higher scores indicating a better outcome.
  • Average patient’s satisfaction.
    • Time Frame: 16 and 24 weeks
    • Average patient’s satisfaction score as assessed by a 9-point anchored visual analogue scale (VAS), ranging from -4 to +4, with negative scores indicating a worsening of condition compared to the untreated control scar, with 0 indicating no difference and with positive scores indicating an improvement.

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent – Skin type I-IV – Presence of >1 scar due to CLE at one localisation – Stable disease (without or with permanent therapy >3months) Exclusion Criteria:

  • History of adverse events related to ablative fractional laser therapy – Ablative resurfacing within the last 6 months on the scar – Pregnant or breast feeding women – Intake of isotretinoin in the last 6 month – Intention to become pregnant during the course of the study – Any scar treatment in the last 3 month before inclusion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital Inselspital, Berne
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kristine Heidemeyer, MD, Principal Investigator, University Hospital Inselspital, Bern
  • Overall Contact(s)
    • Kristine Heidemeyer, MD, 316322218, Kristine.Heidemeyer@insel.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.